Lunch & Learn – Cambridge
PD-1 Cancer Immunotherapy
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressive. Engagement of PD-1 by PD-L1 or PD-L2 results in attenuated TCR signaling and inhibition of T-cell immune functions. Tumors exploit these immune pathways to evade immune eradication. Blockade of the PD-1, PD-L1, and CTLA-4 checkpoints is proving to be an effective and durable cancer immunotherapy in a subset of patients in a broad variety of tumor types by allowing the patient to produce an effective anti-tumor immune response. Expression of PD-L1 by tumor cells or infiltrating immune cells correlates with responsiveness to PD-1 or PD-L1 blockade but is an imperfect biomarker since some patients who do not express PD-L1 still respond. A broad range of other immune modulatory targets has been identified and are potential targets for synergizing with immune checkpoint blockade. Advances in understanding T cell coinhibitory pathways have stimulated a new era of immunotherapy with effective drugs to treat cancer.
Our guest speaker for this event is Gordon J. Freeman, PhD. Dr. Freeman works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. He earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28).
|12:00-12:30||Check-in and lunch|
|12:30-12:45||Dylan Daniel, PhD, Director, Scientific Development – Welcome & Introduction|
|12:45-1:15||Gordon Freeman, PhD – PD-1 Cancer Immunotherapy Presentation|
|1:30-2:00||Wrap up discussion|
Le Méridien Cambridge-MIT
Robert A. Taylor Room
20 Sidney Street
Cambridge, MA 02139 USA
This is a free event, but you need to register to attend. Please register by February 20, 2017.